Tubo-ovarian Abscess

Tubo-ovarian abscess is a polymicrobial inflammatory collection involving the fallopian tube, ovary, or both, most commonly arising as a complication of pelvic inflammatory disease (PID). It occurs in 10–30% of hospitalized PID patients and carries significant morbidity (infertility, chronic pelvic pain, ectopic pregnancy) and potential mortality from rupture and sepsis. [1-2]

1. History

• Chief complaint: Lower abdominal/pelvic pain — the predominant symptom; often progressive and bilateral
• Symptom characterization: Dull, constant pelvic pain; may be unilateral or bilateral; worsened by movement or intercourse
• Timing/triggers: Indolent onset over days; may follow menses, recent IUD insertion, or gynecologic procedure [3]
• Associated symptoms: Fever (present in ~50–88%), nausea/vomiting (~50%), abnormal vaginal discharge, dyspareunia, irregular bleeding, diarrhea [2][4]
• Important negatives: Only a minority present with vaginal symptoms; absence of fever does not exclude TOA [2]
• Key pearl: The triad of fever + leukocytosis + diarrhea should raise suspicion for TOA over uncomplicated PID [4]

2. Alarm Features

• Hemodynamic instability (tachycardia, hypotension) — suggests rupture or sepsis
• Peritoneal signs (rebound, rigidity, guarding) — concerning for ruptured TOA, a surgical emergency
• Rapidly worsening pain with acute deterioration
• High fever (>38.5°C) with signs of systemic toxicity
• Bilateral large abscesses — higher failure rate with antibiotics alone [2][5]
• Postmenopausal TOA — must rule out underlying malignancy [1]

3. Medications

Relevant contributors:

• IUD use (modest risk, primarily in first 3 weeks after insertion)
• Immunosuppressive medications

Treatment — CDC-recommended parenteral regimens: [6]

• First-line: Ceftriaxone 1 g IV q24h + doxycycline 100 mg PO/IV q12h + metronidazole 500 mg PO/IV q12h
• Alternative: Cefotetan 2 g IV q12h + doxycycline 100 mg PO/IV q12h
• Alternative: Cefoxitin 2 g IV q6h + doxycycline 100 mg PO/IV q12h
• For TOA specifically: Clindamycin 900 mg IV q8h + gentamicin (loading 2 mg/kg then 1.5 mg/kg q8h) — provides enhanced anaerobic coverage [6-7]
• Alternative: Ampicillin-sulbactam 3 g IV q6h + doxycycline 100 mg PO/IV q12h — effective against TOA pathogens [6]

Step-down oral therapy: Doxycycline 100 mg BID + metronidazole 500 mg BID (or clindamycin 450 mg QID) to complete 14 days total [6]

Contraindications/cautions:

• Doxycycline: avoid IV if possible due to infusion pain; oral bioavailability is equivalent [6]
• IUD removal is generally not recommended during acute treatment — does not hasten resolution and may delay it [7]

4. Diet

• NPO if surgical intervention is anticipated or if hemodynamically unstable
• Adequate hydration is essential during acute illness
• No specific long-term dietary modifications

5. Review of Systems

• GI: Nausea, vomiting, diarrhea (diarrhea is a distinguishing feature of TOA vs. uncomplicated PID) [4]
• GU: Dysuria, urinary frequency (may mimic UTI), vaginal discharge, abnormal bleeding
• Constitutional: Fever, chills, malaise, anorexia
• Musculoskeletal: Back pain
• RUQ pain: Consider Fitz-Hugh–Curtis syndrome (perihepatitis) [8]

6. Collateral History and Family History

• Sexual history: Number of partners, new partners, condom use, history of STIs
• Gynecologic history: Prior PID episodes, recent IUD placement, recent uterine instrumentation (D&C, HSG, endometrial biopsy)
• Social context: Barriers to follow-up, access to medications
• Important: TOA can occur in non-sexually active patients (especially adolescents) — often from GI flora; do not dismiss the diagnosis based on sexual history alone [9]
• Family history: Not a major contributor, though immunodeficiency states may be hereditary

7. Risk Factors

• History of PID (strongest risk factor)
• Multiple sexual partners
• IUD use (especially recent insertion) [1]
• Recent gynecologic instrumentation (D&C, hysteroscopy, embryo transfer)
• Diabetes mellitus [2]
• Immunosuppression (HIV, transplant, chronic steroids) [1]
• Older age and higher BMI — associated with antibiotic treatment failure [5][10]
• GI source — TOA can arise from appendicitis, diverticulitis, or Crohn's disease [2]

8. Differential Diagnosis

• Ectopic pregnancy — always rule out with β-hCG in reproductive-age women
• Ovarian torsion — acute unilateral pain, often with nausea/vomiting; Doppler US critical
• Appendicitis — RLQ pain; CT can differentiate (right ovarian vein entering a pelvic abscess has 100% specificity for TOA vs. peri-appendiceal abscess) [11]
• Ruptured ovarian cyst — acute onset, often mid-cycle; free fluid on US
• Diverticular abscess — older patients, LLQ pain, CT distinguishes
• Endometrioma — chronic dysmenorrhea, "chocolate cyst" on imaging
• Ovarian malignancy — especially in postmenopausal patients with adnexal mass [3]
• Uncomplicated PID — no discrete abscess on imaging; management differs significantly [12]

9. Past Medical History

• Prior PID or TOA (recurrence risk is significant)
• Prior ectopic pregnancy
• History of STIs (chlamydia, gonorrhea)
• Abdominal/pelvic surgery
• Chronic illnesses: diabetes, HIV, IBD
• Immunosuppressive conditions

10. Physical Exam

Vital signs:

• Fever (>38°C in ~50–88% of cases) [2][4]
• Tachycardia; hypotension if ruptured/septic

Abdominal exam:

• Lower abdominal tenderness (bilateral > unilateral)
• Guarding — independent predictor of need for surgery [13]
• Rebound tenderness — suggests peritonitis/rupture

Pelvic exam:

• Cervical motion tenderness (chandelier sign)
• Adnexal tenderness and/or palpable adnexal mass
• Purulent cervical/vaginal discharge
• Uterine tenderness

Pearl: Physical exam alone has limited sensitivity — a palpable mass is found in only ~50% of cases; imaging is required for definitive diagnosis [2]

11. Lab Studies

Recommended:

• CBC with differential — leukocytosis (WBC often >15,000; mean ~21,800 in TOA vs. ~14,900 in PID alone) [4]
• CRP — the strongest laboratory predictor of TOA; >49.3 mg/L suggests TOA (sensitivity 85%, specificity 93%); serial CRP trending is valuable for monitoring treatment response [14-15]
• ESR — elevated but less specific than CRP
• β-hCG — mandatory to rule out ectopic pregnancy
• Gonorrhea/chlamydia NAAT (cervical or urine)
• Blood cultures — if febrile or septic
• BMP, hepatic panel — baseline for antibiotic dosing and monitoring
• Urinalysis — to exclude UTI/pyelonephritis
• Lactate — if sepsis suspected
• HIV testing — per CDC STI guidelines

Expected abnormalities: Elevated WBC, CRP, ESR; left shift on differential

12. Imaging

First-line: Transvaginal ultrasound (TVUS) [11-12][16]

• Sensitivity 56–93%, specificity 86–98% for TOA
• Findings: complex adnexal mass with varying echogenicity, debris, septations, irregular margins, loss of normal ovarian/tubal boundaries, pyosalpinx, cul-de-sac fluid with internal echoes [11]

CT abdomen/pelvis with IV contrast: [11][17]

• Higher sensitivity than US (100% in one study); better for differentiating GI pathology
• Findings: thick-walled adnexal fluid collection, septations, indistinct borders with adjacent bowel, gas bubbles within the mass (highly specific)
• Useful when US is inconclusive or GI source is suspected

MRI: Best soft-tissue resolution; useful when US and CT are nondiagnostic, especially in pregnant patients [16]

When imaging is unnecessary: Imaging is always required — clinical diagnosis alone is insufficient for TOA [1]

13. Special Tests

Scoring systems:

• Yongue score — uses temperature, CRP, and abscess diameter to predict antibiotic failure (score ≥4 predicts need for intervention; sensitivity 69%, specificity 88%). However, external validation has shown poor discriminatory ability [5][13][18]
• CRP trending — rising CRP over days 1–2 of treatment predicts need for invasive intervention; a <37.1% decrease in CRP by day 4 suggests treatment failure [14-15]

Point-of-care tests:

• Bedside POCUS (transvaginal) — can expedite identification of TOA in the ED [12]
• Wet prep of vaginal discharge

Procedures:

• Image-guided percutaneous drainage (CT- or US-guided) — for abscesses >3 cm failing antibiotics [19]
• Posterior colpotomy drainage — transvaginal approach for cul-de-sac collections

14. ECG

• ECG is not routinely indicated unless:
  • Sepsis with hemodynamic instability (evaluate for sepsis-related cardiac dysfunction)
  • Pre-operative evaluation
  • Tachycardia out of proportion to clinical picture

15. Assessment

Clinical summary: TOA is a high-risk, low-prevalence emergency diagnosis that complicates 10–30% of PID cases. Presentation is often nonspecific — predominantly lower abdominal pain with variable systemic symptoms. Approximately 75% respond to antibiotics alone, but ~25–35% require surgical or interventional drainage. [5][20]

Severity stratification:

• Mild: Small (<5 cm), unilateral, hemodynamically stable, low CRP
• Moderate: 5–8 cm, febrile, elevated CRP (>150 mg/L)
• Severe: >8 cm, bilateral, peritoneal signs, sepsis, or ruptured

Atypical presentations:

• Non-sexually active adolescents (GI flora-driven) [9]
• Postmenopausal women (must exclude malignancy) [1]
• GI-source TOA (appendicitis, diverticulitis) [2]

Complications: Rupture with peritonitis/sepsis (mortality up to 5–10%), infertility, ectopic pregnancy, chronic pelvic pain, recurrence, venous thromboembolism [1]

16. Treatment Plan

Initial stabilization:

• IV access, fluid resuscitation if septic
• Analgesia (NSAIDs ± opioids; NSAIDs do not improve PID outcomes but provide symptomatic relief) [7]
• NPO if surgical intervention anticipated

Antibiotics (start immediately — do not delay for imaging): [6]

• Primary: Ceftriaxone 1 g IV q24h + doxycycline 100 mg PO q12h + metronidazole 500 mg IV/PO q12h
• TOA-specific alternative: Clindamycin 900 mg IV q8h + gentamicin (loading + maintenance) — preferred by some for enhanced anaerobic coverage [7]
• Step-down: After 24–48 hours of clinical improvement → oral doxycycline + metronidazole (or clindamycin) to complete 14 days

Interventional/surgical management:

• Image-guided drainage (CT- or US-guided): for abscesses >3 cm not responding to 48–72 hours of antibiotics; high success rates with lower morbidity than surgery [15][19]
• Laparoscopy: Adhesiolysis, drainage, washout — fertility-sparing
• Laparotomy with salpingo-oophorectomy or TAH/BSO: Reserved for ruptured TOA, failed minimally invasive approaches, or postmenopausal patients [1][8]

Predictors of antibiotic failure (consider early intervention): abscess >6.25 cm, CRP >143.5 mg/L, age >41.5, BMI >26.7, bilateral abscesses, rising CRP on serial monitoring [5][10][14]

17. Disposition

Admission criteria (all TOA patients require admission):

• TOA is an indication for hospitalization per CDC guidelines [6-7]
• 24 hours of inpatient observation is recommended [6]
• IV antibiotics with close monitoring

Observation indications:

Specialist consultation triggers:

• OB/GYN: All cases — for co-management and potential surgical planning
• Interventional radiology: For image-guided drainage when antibiotics fail or large abscess at presentation
• Surgery/general surgery: If GI source suspected (appendiceal or diverticular abscess)
• ICU: Sepsis, hemodynamic instability, ruptured TOA

Discharge criteria:

• Afebrile for 24–48 hours
• Tolerating oral medications
• Improving pain and inflammatory markers (CRP trending down)
• Reliable follow-up arranged

18. Follow Up / Return Precautions

Follow-up timing:

• 48–72 hours after discharge for clinical reassessment
• 2–4 weeks: Repeat imaging (TVUS) to confirm resolution [9]
• STI testing for partners; treat all sexual contacts from the prior 60 days

Symptoms requiring immediate return:

• Worsening abdominal pain or new peritoneal signs
• Fever >38.3°C
• Inability to tolerate oral medications
• Syncope, dizziness, or signs of hemodynamic compromise

Patient counseling:

• Complete the full 14-day antibiotic course
• Abstain from intercourse until treatment is complete and symptoms resolve
• Discuss long-term fertility implications — TOA increases risk of infertility and ectopic pregnancy [1]
• Barrier contraception counseling to reduce future PID/TOA risk

Expected recovery: Clinical improvement typically within 48–72 hours of IV antibiotics. Complete radiologic resolution may take 2–4 weeks. Recurrence risk is significant, and some patients require multiple admissions. [5][9]

References

1. Interventions in Addition to Broad-Spectrum Intravenous Antibiotic Therapy for the Treatment of Radiologically Proven Tubo-Ovarian Abscess. — Boyens H, Bofill Rodriguez M, Wimsett J, et al. The Cochrane Database of Systematic Reviews. 2025.

2. Interventions in Addition to Broad-Spectrum Intravenous Antibiotic Therapy for the Treatment of Radiologically Proven Tubo-Ovarian Abscess. — Boyens H, Bofill Rodriguez M, Wimsett J, et al. The Cochrane Database of Systematic Reviews. 2025.

3. Interventions in Addition to Broad-Spectrum Intravenous Antibiotic Therapy for the Treatment of Radiologically Proven Tubo-Ovarian Abscess. — Boyens H, Bofill Rodriguez M, Wimsett J, et al. The Cochrane Database of Systematic Reviews. 2025.

4. High Risk and Low Prevalence Diseases: Tubo-Ovarian Abscess. — Bridwell RE, Koyfman A, Long B. The American Journal of Emergency Medicine. 2022.

5. High Risk and Low Prevalence Diseases: Tubo-Ovarian Abscess. — Bridwell RE, Koyfman A, Long B. The American Journal of Emergency Medicine. 2022.

6. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. — Committee on Practice Bulletins—Gynecology Obstetrics and Gynecology. 2016.

7. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. — Committee on Practice Bulletins—Gynecology Obstetrics and Gynecology. 2016.

8. Comparative Study of the Clinical Features of Patients With a Tubo-Ovarian Abscess and Patients With Severe Pelvic Inflammatory Disease. — Sordia-Hernández LH, Serrano Castro LG, Sordia-Piñeyro MO, et al. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2016.

9. Comparative Study of the Clinical Features of Patients With a Tubo-Ovarian Abscess and Patients With Severe Pelvic Inflammatory Disease. — Sordia-Hernández LH, Serrano Castro LG, Sordia-Piñeyro MO, et al. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2016.

10. The Tubo-Ovarian Abscess Study (TOAST): A Single-Center Retrospective Review of Predictors of Failed Medical Management. — Marshall A, Wimsett J, Handforth C, et al. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2025.

11. The Tubo-Ovarian Abscess Study (TOAST): A Single-Center Retrospective Review of Predictors of Failed Medical Management. — Marshall A, Wimsett J, Handforth C, et al. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2025.

12. Sexually Transmitted Infections Treatment Guidelines, 2021. — Workowski KA, Bachmann LH, Chan PA, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.

13. Sexually Transmitted Infections Treatment Guidelines, 2021. — Workowski KA, Bachmann LH, Chan PA, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.

14. Pelvic Inflammatory Disease. — Brunham RC, Gottlieb SL, Paavonen J. The New England Journal of Medicine. 2015.

15. Pelvic Inflammatory Disease. — Brunham RC, Gottlieb SL, Paavonen J. The New England Journal of Medicine. 2015.

16. The Management of Intra-Abdominal Infections From a Global Perspective: 2017 WSES Guidelines for Management of Intra-Abdominal Infections. — Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. World Journal of Emergency Surgery : WJES. 2017.

17. The Management of Intra-Abdominal Infections From a Global Perspective: 2017 WSES Guidelines for Management of Intra-Abdominal Infections. — Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. World Journal of Emergency Surgery : WJES. 2017.

18. Tubo-Ovarian Abscess in Non-Sexually Active Adolescent Girls: A Case Series and Literature Review. — Fei YF, Lawrence AE, McCracken KA. Journal of Pediatric and Adolescent Gynecology. 2021.

19. Tubo-Ovarian Abscess in Non-Sexually Active Adolescent Girls: A Case Series and Literature Review. — Fei YF, Lawrence AE, McCracken KA. Journal of Pediatric and Adolescent Gynecology. 2021.

20. Can Antibiotic Treatment Failure in Tubo-Ovarian Abscess Be Predictable?. — Akselim B, Karaşin SS, Demirci A, Üstünyurt E. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2021.

21. Can Antibiotic Treatment Failure in Tubo-Ovarian Abscess Be Predictable?. — Akselim B, Karaşin SS, Demirci A, Üstünyurt E. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2021.

22. ACR Appropriateness Criteria® Acute Pelvic Pain in the Reproductive Age Group: 2023 Update. — Brook OR, Dadour JR, Robbins JB, et al. Journal of the American College of Radiology : JACR. 2024.

23. ACR Appropriateness Criteria® Acute Pelvic Pain in the Reproductive Age Group: 2023 Update. — Brook OR, Dadour JR, Robbins JB, et al. Journal of the American College of Radiology : JACR. 2024.

24. Ultrasound Guidelines: Emergency, Point-of-Care, and Clinical Ultrasound Guidelines in Medicine. — American College of Emergency Physicians (2023). 2023.

25. Ultrasound Guidelines: Emergency, Point-of-Care, and Clinical Ultrasound Guidelines in Medicine. — American College of Emergency Physicians (2023). 2023.

26. Predicting the Need for Surgery in Tubo-Ovarian Abscess: A Clinical Evaluation and External Validation of Risk Scores. — Baer A, Lia M, Weisgerber C, Aktas B, Wolf B. Journal of Minimally Invasive Gynecology. 2026.

27. Predicting the Need for Surgery in Tubo-Ovarian Abscess: A Clinical Evaluation and External Validation of Risk Scores. — Baer A, Lia M, Weisgerber C, Aktas B, Wolf B. Journal of Minimally Invasive Gynecology. 2026.

28. Can the Need for Invasive Intervention in Tubo-Ovarian Abscess Be Predicted? The Implication of C-Reactive Protein Measurements. — Ribak R, Schonman R, Sharvit M, et al. Journal of Minimally Invasive Gynecology. 2020.

29. Can the Need for Invasive Intervention in Tubo-Ovarian Abscess Be Predicted? The Implication of C-Reactive Protein Measurements. — Ribak R, Schonman R, Sharvit M, et al. Journal of Minimally Invasive Gynecology. 2020.

30. Image-Guided Drainage Management of Tubo-Ovarian Abscess and the Role of C-Reactive Protein Measurements in Monitoring Treatment Response: A Single-Center Experience. — Türen Demir E, Energin H, Kilic F. Archives of Gynecology and Obstetrics. 2023.

31. Image-Guided Drainage Management of Tubo-Ovarian Abscess and the Role of C-Reactive Protein Measurements in Monitoring Treatment Response: A Single-Center Experience. — Türen Demir E, Energin H, Kilic F. Archives of Gynecology and Obstetrics. 2023.

32. Evaluation of Acute Pelvic Pain in Women. — Frasca DJ, Jarrio CE, Perdue J. American Family Physician. 2023.

33. Evaluation of Acute Pelvic Pain in Women. — Frasca DJ, Jarrio CE, Perdue J. American Family Physician. 2023.

34. ACR Appropriateness Criteria Acute Nonlocalized Abdominal Pain. — Scheirey CD, Fowler KJ, Therrien JA, et al. Journal of the American College of Radiology : JACR. 2018.

35. ACR Appropriateness Criteria Acute Nonlocalized Abdominal Pain. — Scheirey CD, Fowler KJ, Therrien JA, et al. Journal of the American College of Radiology : JACR. 2018.

36. Tubo-Ovarian Abscess: A Proposed New Scoring System to Guide Clinical Management. — Yongue G, Mollier J, Anin S, et al. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2022.

37. Tubo-Ovarian Abscess: A Proposed New Scoring System to Guide Clinical Management. — Yongue G, Mollier J, Anin S, et al. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics. 2022.

38. ACR Appropriateness Criteria® Radiologic Management of Infected Fluid Collections. — Weiss CR, Bailey CR, Hohenwalter EJ, et al. Journal of the American College of Radiology : JACR. 2020.

39. ACR Appropriateness Criteria® Radiologic Management of Infected Fluid Collections. — Weiss CR, Bailey CR, Hohenwalter EJ, et al. Journal of the American College of Radiology : JACR. 2020.

40. Antibiotic Therapy for Pelvic Inflammatory Disease. — Savaris RF, Fuhrich DG, Maissiat J, Duarte RV, Ross J. The Cochrane Database of Systematic Reviews. 2020.

41. Antibiotic Therapy for Pelvic Inflammatory Disease. — Savaris RF, Fuhrich DG, Maissiat J, Duarte RV, Ross J. The Cochrane Database of Systematic Reviews. 2020.